Should I buy Tilray stock in 2025?

Why trust HelloSafe?

At HelloSafe, our expert has been monitoring Tilray's performance for more than three years. Every month, hundreds of thousands of Canadians count on us to analyze market trends and identify the top investment opportunities. Our analyses are provided for informational purposes only and do not constitute investment advice. In line with our code of ethics, we have never been, and never will be, compensated by Tilray.

What is Tilray?

How much is Tilray stock?

The price of Tilray stock is rising this week. As of now, Tilray shares are trading at $0.49 USD, posting a slight gain of +0.08% over the last 24 hours, despite a weekly decline of -1.38%. The company’s market capitalization stands at $489.96 million, with an average three-month trading volume of approximately 36.99 million shares.

Currently, there is no P/E ratio or dividend yield reported, reflecting ongoing unprofitability and no dividend payments. The stock shows a beta of 1.65, indicating above-average volatility. This higher risk profile may appeal to investors seeking potential rebounds, but it also calls for close attention to market movements.

Our full analysis on Tilray stock

After a thorough review of Tilray Brands, Inc.’s latest financial disclosures and its stock performance over the past three years, our proprietary analysis synthesizes key financial metrics, technical market signals, and an intricate comparison with sector peers. Leveraging both qualitative and quantitative insights, we aim to illuminate the robust foundations and emerging opportunities present in Tilray. So, why might Tilray stock once again become a strategic entry point into the diversified cannabis and wellness sector in 2025?

Recent Performance and Market Context

In the last twelve months, Tilray’s share price has experienced a significant correction, declining nearly 77% year-over-year and settling at $0.4855 as of May 2, 2025—a level near the lower extreme of its 52-week range ($0.43-$2.31). The six-month period preceding this saw a further pullback of 70.4%, a mirror of persistent sector-wide turbulence and evolving investor sentiment around cannabis and related industries.

Yet, beneath the headline numbers, the past quarter has featured notable positive developments:

• Gross margin improvement: Gross profit rose 5% YoY, supported by strategic cost-savings and margin enhancement (gross margin up 200 basis points to 28%).
• Cash flow focus: Cash and marketable securities are a healthy $248 million, buttressed by ongoing debt reduction efforts ($71 million cut, including a $58 million convertible note).
• Segment resilience: Beverage alcohol ($55.9M, 36% margin) and cannabis ($54.3M, 41% margin) remained resilient, with distribution activities (+8% YoY) providing countercyclicality.

From a macro perspective, the landscape is shifting favorably. A convergence of regulatory loosening in core European and Australian markets, combined with growing consumer interest in hemp-derived THC beverages and wellness products, signals structurally improving demand prospects. Emerging ESG frameworks and the sector’s rapid digitalization (notably Tilray’s AI-powered process optimization) also create a supportive context for enterprise value growth.

Technical Analysis

Despite current technical readings that might dissuade near-term momentum traders, a deeper look reveals a constructive setup for longer-term investors:

• Relative Strength Index (RSI) at 38.95: Hovering near “oversold” territory, the RSI suggests potential for an upside reversal from deeply discounted levels.
• MACD at -0.05: While reflecting present bearishness, the distance from recent peaks is narrowing—the kind of technical exhaustion often seen near market lows.
• Moving Averages below price: The 20-, 50-, 100-, and 200-day moving averages are all above the current price, confirming that Tilray is trading at multi-year lows and near major support ($0.43-$0.46). This historically elevates the probability of a reversal or bounce, particularly with growing alignment between fundamentals and technicals.
• Strong support established: The $0.43-$0.46 zone has repeatedly attracted institutional interest, and with Tilray now in proximity, the setup is increasingly attractive for accumulation.

From a short- to medium-term perspective, the overall technical picture, though presently judged “bearish,” actually creates an ideal entry zone for investors seeking asymmetrical risk-reward from a potentially oversold base.

Fundamental Analysis

Tilray’s underlying business transformation is being materially undervalued by the public markets, setting the stage for a recovery phase characterized by operational focus and renewed revenue growth.

Key highlights include:

• Revenue expansion supported by operational discipline: While net revenue was steady at $185.8M (slightly below the prior year due to strategic SKU rationalization), revenues on a constant currency basis were $193M, limiting the impact of currency and portfolio rationalization.
• Profitability priorities: The company’s gross margin reached a notable 28%, with cannabis segment margins shooting to 41% (up 800bps YoY), reflecting executive focus on profitable international channels and intelligent inventory allocation.
• Valuation at historic discounts: Tilray trades at just 0.50x sales and a striking 0.18x book value, a drastic disconnect from sector averages—a level that typically predates value realization as profitability returns. By historical standards, these are not just justified, but potentially attractive valuation multiples given the breadth of Tilray’s diversified platform.
• Expanded market reach and innovation: The beverage segment continues to show robust growth and is now benefiting substantially from Project 420 cost-saving initiatives; together with wellness and distribution, these lines offer resilience and upside in case of sector-specific turbulence.
• Balance sheet strength: Reduced net debt and a net debt/EBITDA ratio below 1x mark one of the healthiest capital structures in the North American cannabis space.

Structural strengths:

• Innovation: AI integrations across supply chains, dynamic product portfolio management, and bold M&A activity underpin Tilray’s role as a sector pioneer.
• Global market share: Strengthening positions in Germany and Australia position the company for outsized international growth.
• Brand recognition: As one of the rare Canadian cannabis names recognized internationally, Tilray commands significant brand equity.

Volume and Liquidity

Sustained trading volumes averaging nearly 37 million shares over three months underscore continued market interest and liquidity. This deep float, combined with a diversified investor base and recent corporate actions (reverse stock split), both ensures access to capital markets and provides fertile soil for dynamic future revaluation. The high trading activity demonstrates that market participants remain actively engaged, creating the context for sharper upside moves as the narrative and fundamentals inflect.

Catalysts and Positive Outlook

Several identifiable catalysts loom on the horizon, each with potential to unlock new shareholder value:

• Project 420: The cost-savings plan—already having realized over $20 million, en route to a $33 million target in beverages—is a direct driver of operating leverage and cash flow.
• Advances in hemp-derived beverages: Distribution has grown to 1,000+ U.S. locations across ten states, pre-empting federal regulatory changes expected to further normalize the U.S. cannabis beverage market.
• AI and process optimization: Early adoption of AI and advanced analytics across Tilray’s global operations is setting a new efficiency benchmark for the industry.
• International expansion: Tilray’s withdrawal from less profitable regions and increased focus on the German and Australian medical markets will likely drive higher-margined, recurring revenue streams.
• Regulatory tailwinds: Ongoing legislative trends in Europe and shifting North American policy sentiment highlight the potential for structurally higher sales channels.
• Reverse stock split: Intended to secure NASDAQ listing compliance, this action often paves the way for catalysts such as institutional re-engagement, index inclusion, and renewed media attention.
• Potential for sector re-rating: As Canada approaches further potential regulatory modernization and capital-light U.S. strategies blossom, entire verticals within cannabis and branded wellness could experience further multiple expansion.

Investment Strategies

Based on our synthesized findings, several strategies appear particularly promising:

• Short-term (1–3 months):
• Play a reversal from historic support: Tilray’s current proximity to $0.43–$0.46 multi-year support offers a low-risk, high-reward setup for nimble buyers.
• Catalyst positioning: Anticipate technical bounce potential surrounding the reverse stock split or targeted corporate announcements.
• Medium-term (3–12 months):
• Benefit from operational inflection: As cost-savings materialize, watch for upward momentum driven by margin expansion and any positive revenue surprises.
• Monitor regulatory signals: Any movement in global cannabis regulation, especially in Germany, could translate to immediate shareholder benefit.
• Long-term (>1 year):
• Participate in sector transformation: As Tilray solidifies its presence across cannabis, beverages, and wellness—coupled with anticipated U.S. policy normalization—the stock may reward patient investors with significant upsides.
• Leverage discounted valuation: The current price/sales and price/book ratios are typically observed at market bottoms, offering long-term value alignment for growth-focused portfolios.

Is It the Right Time to Buy Tilray?

In summary, Tilray Brands presents an unusually compelling convergence of opportunity and value. The company has moved decisively to sharpen its operational model, regain margin leadership, and refocus resources toward its most profitable segments. This fundamental transformation is occurring as the stock hovers near historic lows, supported by robust liquidity and clear technical support.

Looking ahead, the alignment of structural drivers—margin recovery, international growth, regulatory momentum, and financial discipline—signals that the narrative around Tilray may be on the verge of a bullish shift. For investors seeking differentiated exposure to a diversified, innovation-driven cannabis and wellness leader, Tilray’s deep discount to net assets and sales appears to justify renewed consideration. As the sector evolves and Tilray capitalizes on its strategic repositioning, the stock seems poised to offer meaningful upside potential to those ready to embrace the opportunity presented by a recovering industry bellwether.

In a climate where compelling “contrarian” entries can deliver outsize rewards, Tilray stands out as a candidate worthy of careful attention, with the building blocks in place for a notable revaluation as catalysts materialize and investor sentiment resets.

How to buy Tilray stock in Canada?

Buying Tilray stock online is both simple and secure when you choose a regulated broker in Canada. You can invest directly in Tilray shares (“spot” or cash buying), or trade Tilray’s price movements using Contracts for Difference (CFDs). Spot buying lets you become a shareholder, while CFDs allow you to speculate on price changes with leverage. Both approaches are accessible online in just a few clicks, providing flexibility to fit your investment style. For a detailed side-by-side comparison of Canada’s best brokers for Tilray stock—including fees and features—see the comparison table further down this page.

Spot Buying

When you buy Tilray stock for cash, you’re purchasing real shares, making you a direct shareholder with voting rights and potential for capital gains. In Canada, reputable brokers typically charge a fixed commission per trade, often around $5 to $10 CAD.

Example

If Tilray’s share price is $0.49 USD (approx. $0.67 CAD), with $1,000 CAD you can buy about 1,487 shares (considering an estimated brokerage fee of $5 CAD).
✔️ Gain Scenario:
If Tilray’s share price rises by 10%, your shares are now worth $1,100 CAD.
Result: That’s a gross gain of +$100, or +10% on your initial investment.

Trading via CFD

CFD (Contract for Difference) trading enables you to speculate on Tilray’s share price without owning the actual stock. With CFDs, you can use leverage—meaning you can control a larger position with a smaller amount of capital. Fees for CFD trading usually include a spread (difference between buy and sell price) and, if you hold overnight, a daily financing charge.

Example

Suppose you open a CFD position on Tilray shares with $1,000 CAD and use 5x leverage. This exposes you to $5,000 CAD worth of Tilray shares.
✔️ Gain Scenario:
If Tilray’s stock rises by 8%, your CFD position would gain 8% × 5 = 40%.
Result: That’s a $400 CAD gain on your $1,000 outlay—excluding fees (spreads, overnight charges may apply).

Final Advice

Before investing in Tilray stock, it’s essential to compare each broker’s fees, commissions, and trading conditions. The right method—spot buying or CFD trading—depends on your objectives, risk appetite, and investment horizon. Take time to consult the detailed broker comparison available further down the page, so you can invest in Tilray with confidence and clarity.

Platforms

Minimum Deposit

Discover

#1

Tier 1 regulation, including ASIC and FSA

#1

Star Trader

4.9

Minimum Deposit

$50

Discover

with our partner Star Trader

#2

Broker specializing in Forex and CFDs

#2

IFC Markets

4.8

Minimum Deposit

$1

Discover

with our partner IFC Markets

#3

Broker regulated since 2006

#3

Avatrade

4.8

Minimum Deposit

$100

Discover

with our partner Avatrade

Our 7 tips for buying Tilray stock

The latest news about Tilray

Tilray achieved improved gross margins and significant debt reduction in its latest quarterly results. In the most recent Q3 fiscal 2025 snapshot, Tilray reported a gross margin increase to 28%—a 200 basis-point rise year-over-year—driven in part by a notable eight-percentage-point gain in its Canadian cannabis division, now at 41%. The company also successfully reduced total debt by $71 million, with net debt to EBITDA falling below 1x. These developments strengthen Tilray's financial stability, a particularly encouraging signal for the Canadian investor community amid domestic sector headwinds and regulatory pressures.

Cost optimization under “Project 420” has accelerated, with the beverage segment already capturing over $20 million in savings. This cost-savings initiative directly supports Tilray’s Canadian operations, which are a key revenue and employment driver in Ontario and beyond. The company’s focused approach on streamlining its beverage and cannabis segments, as well as leveraging AI innovations for operational efficiency, helps position it as one of the more resilient players within Canada’s increasingly competitive cannabis landscape.

Tilray is successfully expanding advanced cannabis-derived beverage distribution and optimizing Canadian inventories for higher-margin international markets. The company has broadened its distribution of hemp-derived THC beverages in North America, although these products primarily target U.S. states, the operational and supply chain integration in Ontario (Leamington HQ) forms a foundation for scaling similar initiatives for the Canadian market as regulations evolve. Additionally, by redirecting inventory from lower-margin Canadian wholesale toward better-performing international medical markets, Tilray improves overall profitability while navigating domestic overcapacity and pricing challenges.

The announced reverse stock split aims to preserve Tilray’s NASDAQ listing and enhance its market profile. The company’s Board recently moved to consolidate shares, a technical but crucial measure to address minimum bid requirements and maintain access to U.S. capital markets. While this corporate action will not directly affect its Canadian business fundamentals, the company’s continued visibility and compliance on NASDAQ are vital for Canadian stakeholders, ensuring sustained access to international investors and capital.

Tilray’s Canadian operations remain at the core of its global strategy, supported by diversified revenue streams and a growing international footprint. Leamington, Ontario, continues to serve as a strategic hub not only for Canadian cannabis product manufacturing and innovation but also as a base for supporting exports, as evidenced by expansion in regulated European and Australasian medical cannabis markets. Segment growth in Canadian wellness and distribution, together with improved margins and active SKU rationalization, demonstrates Tilray’s ongoing adaptation to market realities and a positive trajectory for its diversified, Canada-rooted business model.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.